FATE
Fate Therapeutics, Inc.
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Best Biotech Stocks 2026 →
Fate Therapeutics (FATE) Stock: Buy, Sell, or Hold?
$1.62
-0.16 (-8.76%)
▼
5d:
-22.73%
30d:
-19.25%
90d:
-35.91%
Open in Live Scanner
70/30 Portfolio Builder
Earnings: Nov 12, 2026
TODAY
Updated Nov 11, 12:00 AM ET
QUANTITATIVE VERDICT
WAIT
LOW Confidence (53%)
Quality Score
37/100
Position
OVERSOLD
30-Day Fair Range
$1.87 – $2.19
Position: OVERSOLD
Forward P/E & Valuation
-1.8x
Next 12M consensus est.
Wall Street Target
$5.72
+223.3% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$1.62 / $2.23
Trend: Downtrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
⏸️ WAIT FOR STABILIZATION: FATE is down 22.7% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Get Alerted When FATE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
In-depth Analysis How we analyze
Valuation Analysis: FATE is currently trading at $1.61, which is considered oversold relative to its 30-day fair value range of $1.87 to $2.19.
Technical Outlook: Technically, FATE is in a downtrend. The price is currently testing key support at $1.62. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.8% recently.
Market Sentiment: FATE scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $5.72 (+223.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, FATE is in a downtrend. The price is currently testing key support at $1.62. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.8% recently.
Market Sentiment: FATE scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $5.72 (+223.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.87 -
$2.19
Company Quality Score
37/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
52.6%
Trading Range & Key Levels
30-Day Trading Range
$1.87 -
$2.19
Current vs Trading Range
OVERSOLD
Support Level
$1.62
Resistance Level
$2.23
Current Trend
Downtrend
Technical data as of
Nov 11, 2026
Quantitative Signal Breakdown
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (30/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-8.8%)
- BULLISH: Trading 223.3% below Wall St target ($5.72)
- WARNING: Composite score 37/100 in the bottom quintile — this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
-1.82
Wall Street Target
$5.72
(+223.3%)
Revenue Growth (YoY)
9.2%
Share FATE Analysis
Share this live FATE analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (FATE)
Bullish
2 Retail Mentions
Reddit / WSB Comments
1
Bearish
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Nov 11, 2026
Daily AI digest
AI Retail Discussion Summary:
Fate Therapeutics presented new FT819 data at ACR Convergence 2026, showcasing meaningful clinical responses in Lupus without conditioning chemotherapy, and opened enrollment for a Phase 1/2 basket trial of FT839.
Key Retail Themes:
Clinical trial data for FT819 in Lupus
Preclinical research on FT839
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 11, 2026 3:03 PM ET
Data refreshes hourly during market hours. Next update: 4:03 PM
Data refreshes hourly during market hours. Next update: 4:03 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is FATE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
24 analysts |
$145 | 31 SELL |
|
ARGX
argenx NV ADR |
STRONG BUY
23 analysts |
$1147 | 35 SELL |
|
BNTX
BioNTech SE |
BUY
21 analysts |
$114 | 62 BUY |
|
IRD
Opus Genetics, Inc. |
STRONG BUY
18 analysts |
$13 | 43 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 39 SELL |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive FATE Research Pages
